-+ 0.00%
-+ 0.00%
-+ 0.00%

Hengrui Pharmaceutical (600276.SH): Application for marketing licensing of repropotide injection accepted

Zhitongcaijing·09/09/2026 09:49:02
Listen to the news

Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company's subsidiary Fujian Shengdi Pharmaceutical Co., Ltd. received the “Notice of Acceptance” issued by the State Drug Administration, and the company's application for a drug marketing license for rupipotide injections was accepted by the State Drug Administration. The drug is intended for glycemic control in adult type 2 diabetics.

According to reports, repropotide is a glucagon-like peptide-1 (GLP-1) and glucose-dependent insulin-promoting peptide (GIP) dual agonist independently developed by the company. It can promote insulin secretion in the body, enhance insulin sensitivity, suppress appetite, and regulate carbohydrate metabolism, thereby improving blood sugar and weight loss. Currently, globally, for T2DM indications, only Eli Lilly's terpotide injection (trade name: Mounjaro) was approved for marketing in the US in May 2022, and in China (trade name: Mu Fengda) in May 2024. According to the EvaluatePharma database, Mounjaro's total global sales in 2025 were approximately US$22.965 billion. Up to now, the total R&D investment in repropeptide-related projects is about 746 million yuan (unaudited).